Ok I'm completely bamboozled now!.
Can someone remind me how MMJ earns revenue?. Where will the considerable value for shareholders come from?. Is it from dividends from investments in Harvest One, e-Sense, Weed Me or Dosecann?.
Where was the $43K in the last quarter from?. Was it from IP or wholesale gelpel sales by Phytotech to Satipharm?. Will retail gelpel sales show up in Satipharm/Harvest Ones financials?.
Why is $595K to be spent on product manufacturing and operational costs next quarter while there was only 5K last quarter?. Is this for the Phase 3 trial?.
I realise the MMJ tortise shell company discusion has already occured earlier and many exited their holdings because of this concern but I have continued to hold in the hope that this would become more evident given time though I must now confess six months later to being non the wiser!..
I always thought that the company vision was for MMJ to be a major "farm to pharma" playa but I have an uneasy feeling that it's shareholders being played having now seen that future performance rights options are at $.45c and less?.
Why is the last investor presentation for MMJ May 2017 and the website still shows latest share price being 35c?.
So many questions, and still so few answers!.
Someone please illuminate me if you have a light!?.
Add to My Watchlist
What is My Watchlist?
